DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 022244
NDA 022244 describes LUSEDRA, which is a drug marketed by Eisai Inc and is included in one NDA. There are two patents protecting this drug. Additional details are available on the LUSEDRA profile page.
The generic ingredient in LUSEDRA is fospropofol disodium. Additional details are available on the fospropofol disodium profile page.
The generic ingredient in LUSEDRA is fospropofol disodium. Additional details are available on the fospropofol disodium profile page.
Summary for 022244
| Tradename: | LUSEDRA |
| Applicant: | Eisai Inc |
| Ingredient: | fospropofol disodium |
| Patents: | 2 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS | Strength | 1050MG/30ML (35MG/ML) | ||||
| Approval Date: | Dec 12, 2008 | TE: | RLD: | No | |||||
| Patent: | ➤ Try a Free Trial | Patent Expiration: | Jul 1, 2022 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patented Use: | SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION | ||||||||
| Patent: | ➤ Try a Free Trial | Patent Expiration: | Aug 7, 2018 | Product Flag? | Substance Flag? | Y | Delist Request? | ||
Complete Access Available with Subscription
